The effect of levofloxacin and moxifloxacin on cardiovascular functions of rats with streptozotocin-induced diabetes

被引:4
作者
Absi, Mais [1 ,2 ]
Ghareeb, Hussam [1 ]
Khalil, Ahmad [1 ]
Ruegg, Urs T. [3 ]
机构
[1] Aleppo Univ, Dept Pharmacol & Toxicol, Aleppo, Syria
[2] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England
[3] Univ Geneva, Sch Pharmaceut Sci, CH-1211 Geneva 4, Switzerland
关键词
Diabetes; EDHF; mesenteric artery; fluoroquinolones; calcium-activated potassium channels; TORSADES-DE-POINTES; POLYMORPHIC VENTRICULAR-TACHYCARDIA; ENDOTHELIAL DYSFUNCTION; INDUCED HYPOGLYCEMIA; ANTIBIOTIC USE; QTC INTERVAL; RISK; FLUOROQUINOLONES; PROLONGATION; RARE;
D O I
10.1177/1479164112445755
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fluoroquinolone antibiotics cause rare, but clinically important, adverse events including hyperglycaemia and hypoglycaemia. The present study focuses on the possible effect of levofloxacin and moxifloxacin on the cardiovascular functions of rats with type I diabetes. Both antibiotics caused bradycardia. Levofloxacin but not moxifloxacin caused hypoglycaemia in diabetic rats and an increase in amplitude of the ST segment revealed by electrocardiogram (ECG) analysis of isolated hearts. In pressurized mesenteric arteries, levofloxacin did not affect the endothelium-derived hyperpolarising factor (EDHF) pathway or its main components, the small-conductance Ca2+ activated potassium (SKca) and intermediate-conductance Ca2+ activated potassium (IKca) channels. In moxifloxacin-treated rats, an increase in the EDHF response was observed, which was largely attributed to SKca-activation. In conclusion, levofloxacin and moxifloxacin use appeared to vary but with no evidence of impairment of the cardiovascular function. However, it is still possible that these antibiotics may produce different effects if there are co-morbidities and therefore their use must be with care.
引用
收藏
页码:65 / 71
页数:7
相关论文
共 38 条
[31]   Effects of Prulifloxacin on Cardiac Repolarization in Healthy Subjects A Randomized, Crossover, Double-Blind versus Placebo, Moxifloxacin-Controlled Study [J].
Rosignoli, Maria Teresa ;
Di Loreto, Giorgio ;
Dionisio, Paolo .
CLINICAL DRUG INVESTIGATION, 2010, 30 (01) :5-14
[32]  
Samaha FF, 1999, AM J MED, V107, P528
[33]   QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder [J].
Serra, DB ;
Affrime, MB ;
Bedigian, MR ;
Greig, G ;
Milosavljev, S ;
Skerjanec, A ;
Wang, YB .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09) :1038-1047
[34]   European Surveillance of Antimicrobial Consumption (ESAC): Data collection performance and methodological approach [J].
Vander Stichele, RH ;
Elseviers, MM ;
Ferech, M ;
Blot, S ;
Goossens, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (04) :419-428
[35]   Endothelial dysfunction and vascular disease [J].
Vanhoutte, P. M. ;
Shimokawa, H. ;
Tang, E. H. C. ;
Feletou, M. .
ACTA PHYSIOLOGICA, 2009, 196 (02) :193-222
[36]   Levofloxacin-induced hypoglycemia in a nondiabetic patient [J].
Wang, Susan ;
Rizvi, Ali A. .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2006, 331 (06) :334-335
[37]   Levofloxacin efficacy in the treatment of community-acquired legionellosis [J].
Yu, VL ;
Greenberg, RN ;
Zadeikis, N ;
Stout, JE ;
Khashab, AA ;
Olson, WH ;
Tennenberg, AM .
CHEST, 2004, 125 (06) :2135-2139
[38]   Effect of Macrolide and Fluoroquinolone Antibacterials on the Risk of Ventricular Arrhythmia and Cardiac Arrest An Observational Study in Italy Using Case-Control, Case-Crossover and Case-Time-Control Designs [J].
Zambon, Antonella ;
Friz, Hernan Polo ;
Contier, Paolo ;
Corrao, Giovanni .
DRUG SAFETY, 2009, 32 (02) :159-167